NEWS legal form changed ByOncoscience 22. August 201717. July 2025 We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson. Ähnliche Beiträge
NEWS Innokeys Pte. Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG ByOncoscience 22. July 201517. July 2025
NEWS Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine. ByOncoscience 17. November 201717. July 2025
NEWS Oncoscience AG announces final results of a phase-II study in pediatric patients with recurrent high-grade malignant glioma treated with the monoclonal antibody NIMOTUZUMAB directed against EGF-R, as monotherapy ByOncoscience 8. June 200717. July 2025
Allgemein | NEWS Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab. ByOncoscience 6. November 202017. July 2025
NEWS Oncoscience signs contract with YM Biosciences Inc. ByOncoscience 15. November 200317. July 2025
